View Item 

Show simple item record

Immunosuppression and the Risk of Post-Transplant Malignancy Among Cadaveric First Kidney Transplant Recipients

dc.contributor.authorBustami, Rami T.en_US
dc.contributor.authorOjo, Akinlolu O.en_US
dc.contributor.authorWolfe, Robert A.en_US
dc.contributor.authorMerion, Robert M.en_US
dc.contributor.authorBennett, William M.en_US
dc.contributor.authorMcDiarmid, Suzanne V.en_US
dc.contributor.authorLeichtman, Alan B.en_US
dc.contributor.authorHeld, Philip J.en_US
dc.contributor.authorPort, Friedrich K.en_US
dc.date.accessioned2010-06-01T20:30:29Z
dc.date.available2010-06-01T20:30:29Z
dc.date.issued2004-01en_US
dc.identifier.citationBustami, Rami T.; Ojo, Akinlolu O.; Wolfe, Robert A.; Merion, Robert M.; Bennett, William M.; McDiarmid, Suzanne V.; Leichtman, Alan B.; Held, Philip J.; Port, Friedrich K. (2004). "Immunosuppression and the Risk of Post-Transplant Malignancy Among Cadaveric First Kidney Transplant Recipients." American Journal of Transplantation 4(1): 87-93. <http://hdl.handle.net/2027.42/73619>en_US
dc.identifier.issn1600-6135en_US
dc.identifier.issn1600-6143en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73619
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14678038&dopt=citationen_US
dc.format.extent105219 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherMunksgaard International Publishersen_US
dc.publisherBlackwell Publishing Ltden_US
dc.rightsBlackwell Munksgaard 2003en_US
dc.subject.otherAntilymphocyte Antibodiesen_US
dc.subject.otherCadaveric Kidney Transplantationen_US
dc.subject.otherDe Novo Tumorsen_US
dc.subject.otherImmunosuppressionen_US
dc.subject.otherInduction Therapyen_US
dc.subject.otherPTLDen_US
dc.subject.otherRisk Factorsen_US
dc.titleImmunosuppression and the Risk of Post-Transplant Malignancy Among Cadaveric First Kidney Transplant Recipientsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumScientific Registry of Transplant Recipients/University of Michigan Kidney Epidemiology and Cost Center, Ann Arbor, MIen_US
dc.contributor.affiliationumDepartment of Veterans Affairs Medical Center, Division of Nephrology, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationumDepartment of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MIen_US
dc.contributor.affiliationumDivision of Transplantation, Department of Surgery, University of Michigan Health System, Ann Arbor, MIen_US
dc.contributor.affiliationotherScientific Registry of Transplant Recipients/University Renal Research and Education Association, Ann Arbor, MIen_US
dc.contributor.affiliationotherSolid Organ and Cellular Transplantation, Legacy Good Samaritan Hospital, and Northwest Renal Clinic, Portland, ORen_US
dc.contributor.affiliationotherPediatric Liver Transplantation, Department of Pediatrics and Surgery, UCLA Medical Center, Los Angeles, CAen_US
dc.identifier.pmid14678038en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73619/1/j.1600-6135.2003.00274.x.pdf
dc.identifier.doi10.1046/j.1600-6135.2003.00274.xen_US
dc.identifier.sourceAmerican Journal of Transplantationen_US
dc.identifier.citedreferenceKew CE 2nd, Lopez-Ben R, Smith JK et al. Posttransplant lymphoproliferative disorder localized near the allograft in renal transplantation. Transplantation 2000; 69: 809 – 814.en_US
dc.identifier.citedreferenceWinkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol 2001; 27: 409 – 413.en_US
dc.identifier.citedreferenceOndrus D, Pribylincova V, Breza J et al. The incidence of tumours in renal transplant recipients with long-term immunosuppressive therapy. Int Urol Nephrol 1999; 31: 417 – 422.en_US
dc.identifier.citedreferenceJain AB, Yee LD, Nalesnik MA et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 66: 1193 – 1200.en_US
dc.identifier.citedreferencePenn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 1996; 2: 52 – 59.en_US
dc.identifier.citedreferenceMihalov ML, Gattuso P, Abraham K et al. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996; 10: 248 – 255.en_US
dc.identifier.citedreferenceBarrett WL, First MR, Aron BS, Penn I. Clinical course of malignancies in renal transplant recipients. Cancer 1993; 72: 2186 – 2189.en_US
dc.identifier.citedreference8.  National Kidney Federation. Cancer after kidney transplantation. Available at: http://www.kidney.org.uk/Medical-Info/transplant/txcancer.html. Accessed May 7, 2003.en_US
dc.identifier.citedreferenceLibertiny G, Watson CJ, Gray DW et al. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001; 88: 1330 – 1334.en_US
dc.identifier.citedreferenceAngel LF, Cai TH, Sako EY, Levine SM. Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center. Ann Transplant 2000; 5: 26 – 30.en_US
dc.identifier.citedreferenceOpelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514 – 1516.en_US
dc.identifier.citedreferenceHolmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002; 6: 456 – 464.en_US
dc.identifier.citedreferenceWinter P, Schoeneich G, Miersch WD, Klehr HU. Tumour induction as a consequence of immunosuppression after renal transplantation. Int Urol Nephrol 1997; 29: 701 – 709.en_US
dc.identifier.citedreferenceYounes BS, McDiarmid SV, Martin MG et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000; 70: 94 – 99.en_US
dc.identifier.citedreferenceJamil B, Nicholls K, Becker GJ, Walker RG. Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 1999; 68: 1597 – 1603.en_US
dc.identifier.citedreference16.  U.S. Renal Data System. USRDS 1998 Annual Data Report. Bethesda, MD: National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases, 1998.en_US
dc.identifier.citedreferenceMelosky B, Karim M, Chui A et al. Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression. J Am Soc Nephrol 1992; 2: S290 – S294.en_US
dc.identifier.citedreferenceMeier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769 – 772.en_US
dc.identifier.citedreference19.  2002 OPTN/SRTR Annual Report 1991–2001. HHS/HRSA/OSP/DOT; UNOS; URREA.en_US
dc.identifier.citedreferenceDickinson DM, Ellison MD, Webb RL. SRTR Report on the State of Transplantation: data sources and structure. Am J Transplant 2003; 3: 13 – 28.en_US
dc.identifier.citedreferenceBates WD, Gray DW, Dada MA et al. Lymphoproliferative disorders in Oxford renal transplant recipients. J Clin Pathol 2003; 56: 439 – 446.en_US
dc.identifier.citedreferenceDharnidharka VR, Sullivan EK, Stablein DM et al. North American Pediatric Renal Transplant Cooperative Study: Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 71: 1065 – 1068.en_US
dc.identifier.citedreferenceCockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001; 3: 70 – 78.en_US
dc.identifier.citedreferenceMontagnino G, Lorca E, Tarantino A et al. Cancer incidence in 854 kidney transplant recipients from a single institution: comparison with normal population and with patients under dialytic treatment. Clin Transplant 1996; 10: 461 – 469.en_US
dc.identifier.citedreferenceHolmes RD, Orban-Eller K, Karrer FR et al. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation 2002; 74: 367 – 372.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1600-6135.2003.00274.x.pdf
Size:
102.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.